Two papers published in the July 1, 2026, issues of Nature and Nature Cancer have reported on preclinical and early clinical data with glycoprotein nonmetastatic melanoma protein B (GPNMB)-targeting CAR T cells in two separate solid tumor types.
Alebund Pharmaceuticals (Jiangsu) Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio Pharma Co. Ltd. and Shaanxi Micot Pharmaceutical Technology Co. Ltd. totaling about HK$4.7 billion (US$600 million).
Total med-tech financing through the first half of 2026 reached $12.28 billion, landing between 2024’s $13.94 billion and 2023’s $10.75 billion over the same period and trailing 2025’s $17.56 billion. The figure reflects a sector that is holding well above the low years of 2022 and 2023.
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Arcutis, Aurenar, Biomerieux, Cogent, Envoy, Hengrui, Monopar, Novaliq, Novocure, Praxis, Roche, Saluda, Sarepta, Starmed, Unicycive.
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Candela, Cerenome, Eli Lilly, Innovent, Kyowa, Orion, Pacira, Plus, Shilpa, Zimmer.
Clinical updates for biopharma and med tech, including data readouts and publications: Abivax, Abbvie, AC Immune, Ascendis, Beone, Catalyst, Cogent, Genelux, Genmab, Moleculin, Pasithea, Sanofi, Skyhawk, Vistagen, Vivos.
Regardless of whether the Republicans or Democrats come out on top in November’s midterm congressional elections, some of the state primaries in the U.S. have already guaranteed major shuffles in key House and Senate committees overseeing national health issues.
Zimmer Biomet Holdings Inc.’s deal to buy Pacira Biosciences Inc.’s Iovera system for up to $140 million and Eurobio Scientific SA’s acquisition of Caredx Inc.’s lab products business for $171.2 million are symptomatic of a broader trend among med-tech and diagnostics companies using targeted acquisitions to strengthen specific areas of their portfolio.
RSS
